Medications for Generalized Anxiety Disorder: Neurobiology
This paper examines the pharmacological treatment of Generalized Anxiety Disorder (GAD), focusing on the neurobiology and mechanisms of action of two primary medication classes: antidepressants and benzodiazepines. Within antidepressants, the paper discusses selective serotonin reuptake inhibitors (SSRIs) — including fluoxetine, sertraline, paroxetine, and citalopram — and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), specifically venlafaxine and duloxetine. It also covers benzodiazepines, particularly alprazolam, which is the only FDA-approved drug in that class for GAD. The paper concludes by noting that combining pharmacotherapy with cognitive behavioral therapy may yield the best outcomes for patients.
- Introduction: Defines GAD and scopes pharmacological discussion
- Antidepressants as First-Line GAD Medications: Overview of antidepressants as primary GAD treatment
- Selective Serotonin Reuptake Inhibitors (SSRIs): Mechanisms and examples of SSRI drugs
- Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine and duloxetine mechanisms and efficacy
- Benzodiazepines in GAD Treatment: GABA-based CNS depressants and FDA approvals
- Conclusion: Combined pharmacotherapy and psychotherapy outcomes
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Organizes a complex pharmacological topic into clearly delineated medication classes, making the material accessible and logically progressive.
- Consistently pairs drug names with their specific mechanisms of action, grounding clinical claims in neurobiological explanation.
- Distinguishes between FDA-approved and off-label uses, demonstrating awareness of regulatory context alongside clinical evidence.
Key academic technique demonstrated
The paper effectively uses comparative analysis to differentiate between medication classes — for example, contrasting SSRIs (serotonin only) with SNRIs (serotonin and norepinephrine) and benzodiazepines (GABA modulation) — helping readers understand not just what each drug does, but how the classes relate to one another neurobiologically.
Structure breakdown
The paper follows a clear hierarchical structure: a brief introduction defines GAD and scopes the discussion; the body moves from antidepressants (subdivided into SSRIs and SNRIs, each with drug-by-drug breakdowns) to benzodiazepines; and a short conclusion situates pharmacotherapy within the broader treatment landscape including psychotherapy. This scaffold mirrors a clinical review format appropriate for a psychobiology course.
Introduction
From time to time, most people feel anxious about diverse events or occurrences in life — this is normal. However, when anxiety is persistent, exaggerated, and/or excessive, a person may be suffering from Generalized Anxiety Disorder (GAD). In the past, various interventions have been formulated in an attempt to treat this condition. The main treatment approaches are medications and psychotherapy. This paper concerns itself with the medications approved in the treatment of GAD, with the main focus on neurobiology and drug mechanisms of action.
Antidepressants as First-Line GAD Medications
There are various medications that have proven effective and have thus been approved for the treatment of GAD. These medications are especially instrumental in efforts to ease symptoms of the condition. The two major medication classes considered here are antidepressants and benzodiazepines.
As Gerlach and Gloster (2020) point out, antidepressants are considered first-line medications in the treatment of GAD — that is, they are routinely used as the first choice of medication for patients diagnosed with the condition. Unlike benzodiazepines, which are usually used for short-term treatment, antidepressants are employed in the longer-term management of GAD. Two important antidepressant subclasses in this context are selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs).
Selective Serotonin Reuptake Inhibitors (SSRIs)
Regarding SSRIs, Gerlach and Gloster (2020) are clear that "as the name suggests, SSRIs exert action by inhibiting the reuptake of serotonin, thereby increasing serotonin activity" (p. 213). It therefore follows that SSRIs' therapeutic effect is largely founded upon their ability to increase deficient serotonin. However, as Strawn, Geracioti, Tajdev, Clemenza, and Levine (2019) indicate, in some instances SSRIs faintly inhibit the reuptake mechanisms for dopamine and norepinephrine as well. As a neurotransmitter, serotonin is instrumental in relaying messages between neurons; more serotonin — specifically at the postsynaptic membrane in the synapse — effectively means better transmission of those messages. Examples of SSRIs include fluoxetine, sertraline, paroxetine, and citalopram.
With regard to fluoxetine, Strawn et al. (2019) note that this was one of the first SSRIs introduced in the country, in the 1970s. Its therapeutic effect is largely rooted in its ability to increase serotonergic transmission, though the drug has also been shown to have dopaminergic and noradrenergic effects. According to Gerlach and Gloster (2020), the drug is well tolerated among both pediatric and adult patients diagnosed with GAD.
Sertraline has also proven effective in the treatment of GAD. In a study evaluating this drug among pediatric patients presenting with GAD symptoms, it was found that in comparison to a placebo, sertraline brought about significant improvements in symptom reduction (Strawn et al., 2019). The authors further indicate that among adults, the therapeutic effect of sertraline is enhanced when combined with cognitive behavioral therapy (CBT).
Paroxetine, in the words of Strawn et al. (2019), "potently inhibits 5-HT reuptake and also blocks some reuptake of norepinephrine" (p. 1060). Research conducted to date has indicated that this drug is effective in the treatment of GAD among adult patients.
Citalopram is one of the more recently introduced SSRIs. Gerlach and Gloster (2020) point out that in comparison to other SSRIs, the drug is notably selective in its transportation of serotonin. It should also be noted that citalopram, unlike other drugs in this category, does not undergo first-pass metabolism (Strawn et al., 2019).
Conclusion
In addition to the medications highlighted above, other effective treatment approaches include psychotherapy — with cognitive behavioral therapy (CBT) being the most common form used in this context. In practice, a combination of pharmacotherapy, as described above, and psychotherapy may be of the greatest benefit to persons diagnosed with GAD.
References
Durbano, F. (2013). New Insights into Anxiety Disorders. BoD.
Gerlach, A. & Gloster, A. (2020). Generalized Anxiety Disorder and Worrying: A Comprehensive Handbook for Clinicians and Researchers. John Wiley & Sons.
Marker, C. & Aylward, A. (2011). Generalized Anxiety Disorder. Hogrefe Publishing.
Schlaepfer, T. E. & Nemeroff, C. B. (2012). Neurobiology of Psychiatric Disorders. Elsevier.
Strawn, J. R., Geracioti, L., Tajdev, N., Clemenza, K., & Levine, A. (2019). Pharmacotherapy for generalized anxiety disorder in adults and pediatric patients: An evidence-based treatment review. Expert Opinion on Pharmacotherapy, 19(10), 1057–1070.
Always verify citation format against your institution’s current style guide requirements.